ALX Oncology Holdings

ALX Oncology Holdings is a clinical-stage biotechnology company based in South San Francisco that engineers therapies designed to help the immune system fight cancer. Its lead asset, evorpacept, is a CD47-blocking fusion protein pairing a high-affinity SIRPalpha domain with an inactive Fc region, developed to relieve the 'don't eat me' signal that tumour cells use to evade macrophage clearance and to be combined with antibody-based regimens. The company is running biomarker-selected mid-stage programmes in HER2-positive gastric and gastroesophageal junction cancer and HER2-positive breast cancer, and is advancing ALX2004, an EGFR-targeted antibody-drug conjugate, in EGFR-expressing solid tumours. ALX Oncology has no approved products or product revenue and funds operations from its cash balance and public equity markets; it has traded on the Nasdaq Global Select Market under the ticker ALXO since its 2020 initial public offering and closed below $1.00 for the first time on October 13, 2026, versus a 52-week range of $1.05 to $2.66.